Pfizer says its vaccine continues to be effective against COVID-19 up to six months later.
Pfizer and its German partner, BioNTech, announced updated results Thursday from their ongoing late-stage study of more than 44,000 volunteers.
The companies said the vaccine was 91% effective against symptomatic disease and was even more protective in preventing severe disease. Of 927 confirmed COVID-19 cases detected through March 13, 77 were among people who received the vaccine and 850 were among people who got dummy shots.
There were no serious safety concerns and the vaccine also appeared to work against a variant first detected in South Africa, the companies said.
The U.K. and U.S. gave the emergency green light to roll out Pfizer’s vaccine late last year followed by many other countries. The vaccine is authorized for ages 16 and up.
This week, the companies said the vaccine is safe and strongly protective in kids as young as 12, based on a study of 2,260 U.S. volunteers.
Northwestern Mutual’s A.I. and money report shows that consumers want their adviser to take advantage of ‘superpowers’ granted by artificial intelligence tools.
The FDRA is a trade association that supports nearly 500 brands worldwide including Nike, Adidas, Walmart, and Target and represents over 90% of US shoe sales.
Lead Analyst at TVREV, Alan Wolk, joins Cheddar to discuss the latest in media and business news, including why business at the box office may be slowing down.
With stubborn inflation sticking at about 2.8%, there’s a chance that the Fed won’t cut rates this year. That might be the smarter choice in the long run.
